Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 14 points (-0.1%) at 15,098 as of Friday, Aug. 16, 2013, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,393 issues advancing vs. 1,555 declining with 92 unchanged. The Drugs industry currently is unchanged today versus the S&P 500, which is down 0.1%. A company within the industry that increased today was Biogen Idec ( BIIB), up 0.5%. A company within the industry that fell today was Eli Lilly and Company ( LLY), up 0.7%. TheStreet would like to highlight 4 stocks pushing the industry higher today: 4. Shire ( SHPG) is one of the companies pushing the Drugs industry higher today. As of noon trading, Shire is up $1.01 (0.9%) to $111.70 on average volume. Thus far, 226,342 shares of Shire exchanged hands as compared to its average daily volume of 377,200 shares. The stock has ranged in price between $111.20-$111.84 after having opened the day at $111.65 as compared to the previous trading day's close of $110.69. Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $20.9 billion and is part of the health care sector. Shares are up 20.7% year to date as of the close of trading on Thursday. Currently there are 9 analysts that rate Shire a buy, no analysts rate it a sell, and 3 rate it a hold. TheStreet Ratings rates Shire as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Shire Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.